Ryan CJ, et al. - Researchers assessed data from 1,050 men treated on CALGB 90401 with docetaxel, prednisone and either bevacizumab or placebo to determine how the decline in serum androgen levels (testosterone (T), androstenedione (A) and DHEA) in docetaxel-treated mCRPC patients is associated with overall survival (OS). For T, A, and, DHEA, median baseline values were 1.0, 13.5, and 8.1 ng/dL respectively; 6-week levels were 0.64, 7.0, and 6.8 ng/dL respectively. Outcomes revealed a longer survival in correlation to declines in testosterone during docetaxel treatment. This was consistent with a favorable prognostic significance of higher serum androgens in the CRPC.